Cardlytics Days Sales Outstanding vs Operating Cash Flow Per Share Analysis
CDLX Stock | USD 9.40 0.63 7.18% |
Cardlytics financial indicator trend analysis is way more than just evaluating Cardlytics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardlytics is a good investment. Please check the relationship between Cardlytics Days Sales Outstanding and its Operating Cash Flow Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardlytics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Cardlytics Stock please use our How to Invest in Cardlytics guide.
Days Sales Outstanding vs Operating Cash Flow Per Share
Days Sales Outstanding vs Operating Cash Flow Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardlytics Days Sales Outstanding account and Operating Cash Flow Per Share. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Cardlytics' Days Sales Outstanding and Operating Cash Flow Per Share is -0.47. Overlapping area represents the amount of variation of Days Sales Outstanding that can explain the historical movement of Operating Cash Flow Per Share in the same time period over historical financial statements of Cardlytics, assuming nothing else is changed. The correlation between historical values of Cardlytics' Days Sales Outstanding and Operating Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Sales Outstanding of Cardlytics are associated (or correlated) with its Operating Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Cash Flow Per Share has no effect on the direction of Days Sales Outstanding i.e., Cardlytics' Days Sales Outstanding and Operating Cash Flow Per Share go up and down completely randomly.
Correlation Coefficient | -0.47 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Days Sales Outstanding
Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Most indicators from Cardlytics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardlytics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardlytics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Cardlytics Stock please use our How to Invest in Cardlytics guide.Tax Provision is likely to rise to 0.00 in 2024, whereas Selling General Administrative is likely to drop slightly above 48.4 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 35.7M | 43.7M | 29.5M | 16.8M | Interest Income | 297K | 1.4M | 3.8M | 3.4M |
Cardlytics fundamental ratios Correlations
Click cells to compare fundamentals
Cardlytics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cardlytics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 224.3M | 422.5M | 1.3B | 691.2M | 574.1M | 440.0M | |
Short Long Term Debt Total | 37K | 188.1M | 197.2M | 235.3M | 266.1M | 138.7M | |
Other Current Liab | 76.0M | 74.8M | 313.4M | 238.5M | 162.2M | 126.0M | |
Total Current Liabilities | 78.4M | 81.3M | 327.4M | 248.9M | 171.1M | 135.4M | |
Total Stockholder Equity | 143.3M | 157.2M | 690.7M | 211.6M | 134.8M | 98.0M | |
Other Liab | 2.6M | 679K | 54.5M | 334K | 384.1K | 364.9K | |
Net Tangible Assets | 139.1M | 150.4M | (190.5M) | 158.1M | 181.8M | 190.9M | |
Property Plant And Equipment Net | 14.3M | 24.6M | 21.5M | 12.5M | 10.6M | 14.5M | |
Current Deferred Revenue | 1.1M | 349K | 3.3M | 1.8M | 2.4M | 1.3M | |
Net Debt | (104.4M) | (105.1M) | (36.2M) | 113.4M | 174.3M | 183.0M | |
Retained Earnings | (338.6M) | (394.1M) | (522.6M) | (976.6M) | (1.1B) | (1.1B) | |
Accounts Payable | 1.2M | 1.4M | 4.6M | 3.8M | 4.4M | 3.2M | |
Cash | 104.5M | 293.2M | 233.5M | 121.9M | 91.8M | 116.8M | |
Non Current Assets Total | 28.6M | 36.9M | 905.1M | 441.2M | 350.2M | 226.1M | |
Non Currrent Assets Other | 10.1M | 5.6M | 2.4M | 2.6M | 2.7M | 2.6M | |
Other Assets | 10.1M | 22.6M | 2.4M | 2.6M | 2.3M | 2.2M | |
Long Term Debt | 13K | 174.0M | 184.4M | 226.0M | 257.6M | 130.8M | |
Cash And Short Term Investments | 104.5M | 293.2M | 233.5M | 121.9M | 91.8M | 116.8M | |
Net Receivables | 85.4M | 86.6M | 117.2M | 120.1M | 126.0M | 89.2M | |
Common Stock Shares Outstanding | 23.7M | 27.2M | 32.2M | 33.4M | 36.5M | 26.9M | |
Long Term Debt Total | 13K | 174.0M | 184.4M | 226.0M | 260.0M | 273.0M | |
Liabilities And Stockholders Equity | 224.3M | 422.5M | 1.3B | 691.2M | 574.1M | 440.0M | |
Non Current Liabilities Total | 2.6M | 184.1M | 245.7M | 230.7M | 268.2M | 206.5M | |
Capital Surpluse | 480.6M | 551.4M | 1.2B | 1.2B | 1.4B | 1.4B | |
Inventory | 129K | 110K | 95K | 80K | 72K | 68.4K | |
Other Current Assets | 5.8M | 5.7M | 8.0M | 8.0M | 6.1M | 5.2M | |
Other Stockholder Equity | 480.6M | 551.4M | 1.2B | 1.2B | 1.2B | 628.4M | |
Total Liab | 81.0M | 265.3M | 573.1M | 479.6M | 439.3M | 342.0M | |
Deferred Long Term Liab | 8.5M | 3.8M | 139K | 198K | 178.2K | 169.3K | |
Property Plant And Equipment Gross | 14.3M | 24.6M | 11.3M | 5.9M | 43.7M | 45.9M | |
Total Current Assets | 195.7M | 385.6M | 358.7M | 250.0M | 223.9M | 213.8M | |
Accumulated Other Comprehensive Income | 1.3M | (192K) | 486K | 5.6M | 2.5M | 1.9M | |
Short Term Debt | 24K | 4.7M | 6.0M | 4.9M | 2.1M | 3.6M | |
Intangible Assets | 4.2M | 6.7M | 138.7M | 73.4M | 59.6M | 35.1M | |
Property Plant Equipment | 14.3M | 13.9M | 21.5M | 5.9M | 6.8M | 12.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cardlytics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cardlytics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cardlytics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cardlytics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardlytics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Cardlytics Stock please use our How to Invest in Cardlytics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Cardlytics Stock analysis
When running Cardlytics' price analysis, check to measure Cardlytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardlytics is operating at the current time. Most of Cardlytics' value examination focuses on studying past and present price action to predict the probability of Cardlytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardlytics' price. Additionally, you may evaluate how the addition of Cardlytics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Cardlytics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardlytics. If investors know Cardlytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardlytics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.57) | Earnings Share (4.66) | Revenue Per Share 8.033 | Quarterly Revenue Growth 0.051 | Return On Assets (0.06) |
The market value of Cardlytics is measured differently than its book value, which is the value of Cardlytics that is recorded on the company's balance sheet. Investors also form their own opinion of Cardlytics' value that differs from its market value or its book value, called intrinsic value, which is Cardlytics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardlytics' market value can be influenced by many factors that don't directly affect Cardlytics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardlytics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardlytics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardlytics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.